Rituximab in combination with conformal radiotherapy treatment of postoperative primary central nervous system lymphoma
10.3760/cma.j.issn.1009-9921.2012.03.008
- VernacularTitle:利妥昔单抗联合适形放疗治疗术后原发中枢神经系统淋巴瘤的疗效分析
- Author:
Qingfeng LI
;
Juan ZHANG
;
Qingfeng ZHOU
;
Yingying LIU
;
Tienan YI
;
Siqing NING
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Central nervous system neoplasms;
Rituximab;
3-dimentional conformal radiotherapy dosage
- From:
Journal of Leukemia & Lymphoma
2012;21(3):157-158,162
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the long-term results of rituximab combined with whole brain radiotherapy and 3-dimentional conformal radiotherapy (3D-CRT) in treatment of patients with primary central nervous system lymphoma (PCNSL). Methods 23 postoperative patients younger than 60 years old were treated. Whole brain radiotherapy with dose of 32.4 Gy were performed and lesions were followed by 3D-CRT with dose of 18 Gy.A dose of rituximab (375 mg/m2) was infused on day 1 (once a week for six weeks).The overall survival was analyzed by using Kaplan-Meier.Results 19 patients(82.6 ％) was complete remission 3 patients (13.0 ％) was part remission,14 patients (60.9 ％) was progression-free survival was 26 months (17-34 months). The overall survival was 40 months (29-55 months). Toxicity was moderate without grade 3-4 neurotoxicity toxic events. Conclusions Radiotherapy (whole brain radiotherapy with sequential 3D-CRT)combined with rituximab seems to yield substantial long-term survival with moderate toxicity for the treatment of the younger patients with PCNSL.
